Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Postoperative Infection Rates in Patients with a Negative Baseline Urine Culture Undergoing Ureteroscopic Stone Removal: A Matched Case–Control Analysis on Antibiotic Prophylaxis from the CROES URS Global Study
Мартов, А Г, Gravas, Stavros , Etemadian, Masoud , Ünsal, Ali , Barusso, Gabriel, D’Addessi, Alessandro, Krambeck, Amy E. , Rosette, Jean de la

Journal of Endourology | July 29, 2014 | Volume: 29 | Issue: 2 | Pages: 171-180

10.1089/end.2014.0470 | PMID 25072350 Get It

Purpose: To examine the effects of antibiotic prophylaxis on postoperative infection rate in patients with negative urine cultures undergoing ureteroscopy (URS). Patients and Methods: Using the Clinical Research Office of the Endourological Society (CROES) URS Global Study database, patients with a negative baseline urine culture undergoing URS for ureteral stones ( n =1141) or kidney stones ( n =184) not receiving antibiotic prophylaxis were matched with those who were predefined by risk factors, including gender, American Society of Anesthesiologists (ASA) score, and ureteral stent placement. Patient characteristics, operative data, and postoperative outcomes, including the development of urinary tract infection (UTI) and fever, in the two groups were compared. Results: Antibiotic prophylaxis use differed widely across participating countries (13%–100%). Differences were found between patients who did or did not receive antibiotic prophylaxis regarding the frequency of anticoagulation medication, previous treatment with URS, stone burden, previous presence of kidney stones, duration of current URS, and complications post-URS. The prevalence of fever and UTI was low (≤2.2%) and similar in both groups. Factors predictive of postoperative UTI or fever were female gender, Crohn's and cardiovascular disease, a high stone burden, and an ASA score of II or higher. Conclusions: In patients with a negative baseline urine culture undergoing URS for ureteral or renal stones, rates of postoperative UTI and fever were not reduced by preoperative antibiotic prophylaxis. Female gender and a high ASA score were specific risk factors for postoperative infection in this patient group.
Cardiovascular Risk and Acute Coronary Syndrome in Giant Cell Arteritis: A Population‐Based Retrospective Cohort Study
Udayakumar, Prabhu D., Crowson, Cynthia S. , Warrington, Kenneth J. , Matteson, Eric L. , Chandran, Arun Kumar , Warrington, Kenneth J

Arthritis Care & Research | July 29, 2014 | Volume: 67 | Issue: 3 | Pages: 396-402

10.1002/acr.22416 | PMID 25074472 Get It

Objective To assess the occurrence of acute coronary syndrome (ACS) in patients with giant cell arteritis (GCA) compared to subjects without GCA. Methods We retrospectively reviewed a population‐based incidence cohort of Olmsted County, Minnesota residents with GCA diagnosed in 1950–2009. We compared this cohort with a cohort of patients without GCA of similar age, sex, and calendar year from the same population. Results The study included 245 patients with GCA and 245 non‐GCA subjects. The mean ± SD Framingham cardiovascular risk score was 30% ± 19% in GCA patients and 34% ± 23% in non‐GCA subjects ( P = 0.096) at the incidence/index date. Diabetes mellitus was significantly less common in GCA patients than non‐GCA subjects at the index date. The mean high‐density lipoprotein was higher and triglycerides were lower, with fewer patients taking lipid‐lowering medications in the GCA cohort compared to the non‐GCA cohort at the index date. During followup, no difference between the 2 cohorts was noted in the overall rate of ACS events (hazard ratio 0.74, 95% confidence interval 0.44–1.26). Overall thrombosis in myocardial infarction scores were similar in both cohorts. Revascularization procedures were done less frequently in GCA than in non‐GCA subjects (19% versus 50%; P = 0.015). Post‐ACS hospital length of stays and complications were similar in both cohorts. Conclusion Multiple cardiovascular risk factors are less atherogenic at incidence of GCA. There is no overall increased risk of ACS in patients with GCA.
Diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome: retrospective single site study and literature review of 225 patients
Barrick, Benjamin J., Pittelkow, Mark R. , Peller, Patrick J., Camilleri, Michael , Lehman, Julia S. , Lehman, Vance T. , Lehman, Julia S

International Journal of Dermatology | July 29, 2014 | Volume: 54 | Issue: 4 | Pages: 424-437

10.1111/ijd.12603 | PMID 25069905 Get It

AbstractBackgroundThe utility of diagnostic imaging in paraneoplastic autoimmune multiorgan syndrome (PAMS) is unknown.MethodsWe examined the role of diagnostic imaging in patients with PAMS evaluated at our tertiary referral center (at Mayo Clinic, Rochester, MN, USA) and in the English literature between January 1, 1996, and August 31, 2012.ResultsWe included 17 patients from our institution and 208 patients from the literature review. Of these 225 patients, 113 (50.2%) were not known to have a malignancy diagnosis at the time of PAMS diagnosis. Of the 123 patients from our institution and from the literature reported to undergo imaging studies, conventional computed tomography (CT) was the predominant imaging modality (n = 110; 89.4%); 18F‐fluorodeoxyglucose (18F‐FDG) positron emission tomography (PET)/CT was also used, albeit infrequently (n = 12; 9.8%). When CT was included in imaging to identify or confirm the presence of a malignancy, imaging was successful in all patients who ultimately were diagnosed with an associated malignancy. At our institution, a relatively high percentage (n = 7; 41%) of patients had 18F‐FDG PET/CT, which not only identified all tumors found on CT but also facilitated staging of lymphoma and guided biopsy procedures.ConclusionDiagnostic imaging is frequently utilized in PAMS with unknown malignancy. Both conventional CT and 18F‐FDG PET/CT are likely to detect the typical underlying neoplasms. Relative to conventional CT, 18F‐FDG PET/CT may provide additional useful information regarding prognosis for the likely underlying malignancies, although there is a paucity of reports describing the use of this modality for this purpose.
Reply to D.M. Hyman et al and M. Voskoboynik et al
Ballman, Karla V.

Journal of Clinical Oncology | July 29, 2014 | Volume: 32 | Issue: 28 | Pages: 3200-3200

10.1200/jco.2014.56.5770 | PMID 25071106 Get It

Incorporating Biomarkers Into Cancer and Aging Research
Cohen, Harvey Jay, Muss, Hyman B. , Hubbard, Joleen M. , Cohen, Harvey J

Journal of Clinical Oncology | July 29, 2014 | Volume: 32 | Issue: 24 | Pages: 2611-2616

10.1200/jco.2014.55.4261 | PMID 25071114 Get It

The challenge in treating the older adult with cancer is accurately accounting for and adapting management to the heterogeneity in health status of the individual patient. Many oncologists recognize that chronological age alone should not be the determinant when deciding on a treatment regimen. Easily measurable markers that provide an assessment of functional age would be ideal to assess frailty, which may predispose the patient to complications from cancer treatment, including increased toxicity, functional decline, decreased quality of life, and poorer survival. Several categories of potential markers, including chronic inflammatory markers, markers of cellular senescence, and imaging to assess muscle mass to detect sarcopenia, may provide insight into the likelihood of treatment-related complications. This article discusses candidate markers and strategies to evaluate these markers in cancer treatment trials, with the aim of developing a method to assess risk of oncologic outcomes and guide management decisions for both the physician and patient.
Non–Small-Cell Lung Cancer in Elderly Patients: A Discussion of Treatment Options
Jatoi, Aminah , Gajra, Ajeet

Journal of Clinical Oncology | July 29, 2014 | Volume: 32 | Issue: 24 | Pages: 2562-2569

10.1200/jco.2014.55.3099 | PMID 25071101 Get It

Lung cancer is a disease of the elderly. In older patients, the management of a malignancy as complex and potentially as lethal as lung cancer is challenging. Despite the fact that a large proportion of patients with non–small-cell lung cancer are elderly, information remains scant on how best to treat these patients. The goal of this review is to discuss the published literature and to provide guidance on how to treat elderly patients within three broad stages: (1) metastatic cancer, (2) early-stage cancer after surgery, and (3) locally advanced inoperable cancer. Because decisions on how and when to prescribe systemic treatment can be particularly difficult, this review focuses heavily on chemotherapy-related treatment decisions with some discussion of emerging data on the use of the comprehensive geriatric assessment.
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Adams, Sylvia , Demaria, Sandra , Goldstein, Lori J. , Perez, Edith A. , Martino, Silvana, Jones, Vicky, Saphner, Thomas J. , Wolff, Antonio C. , Wood, William C., Davidson, Nancy E. , Sparano, Joseph A. , Gray, Robert J. , Shulman, Lawrence N. , Wang, Molin , Sledge, George W. , Badve, Sunil , Wolff, Antonio C , Sparano, Joseph A

Journal of Clinical Oncology | July 28, 2014 | Volume: 32 | Issue: 27 | Pages: 2959-2966

10.1200/jco.2013.55.0491 | PMID 25071121 Get It

Purpose Recent studies suggest that tumor-infiltrating lymphocytes (TILs) are associated with disease-free (DFS) and overall survival (OS) in operable triple-negative breast cancer (TNBC). We seek to validate the prognostic impact of TILs in primary TNBCs in two adjuvant phase III trials conducted by the Eastern Cooperative Oncology Group (ECOG). Patients and Methods Full-face hematoxylin and eosin–stained sections of 506 tumors from ECOG trials E2197 and E1199 were evaluated for density of TILs in intraepithelial (iTILs) and stromal compartments (sTILs). Patient cases of TNBC from E2197 and E1199 were randomly selected based on availability of sections. For the primary end point of DFS, association with TIL scores was determined by fitting proportional hazards models stratified on study. Secondary end points were OS and distant recurrence–free interval (DRFI). Reporting recommendations for tumor marker prognostic studies criteria were followed, and all analyses were prespecified. Results The majority of 481 evaluable cancers had TILs (sTILs, 80%; iTILs, 15%). With a median follow-up of 10.6 years, higher sTIL scores were associated with better prognosis; for every 10% increase in sTILs, a 14% reduction of risk of recurrence or death (P = .02), 18% reduction of risk of distant recurrence (P = .04), and 19% reduction of risk of death (P = .01) were observed. Multivariable analysis confirmed sTILs to be an independent prognostic marker of DFS, DRFI, and OS. Conclusion In two national randomized clinical trials using contemporary adjuvant chemotherapy, we confirm that stromal lymphocytic infiltration constitutes a robust prognostic factor in TNBCs. Studies assessing outcomes and therapeutic efficacies should consider stratification for this parameter.
Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference Recommendations
Hurria, Arti , Dale, William , Mooney, Margaret , Rowland, Julia H. , Cohen, Harvey Jay, Muss, Hyman B. , Schilsky, Richard L. , Extermann, Martine , Schmader, Kenneth E. , Mohile, Supriya G. , Ballman, Karla V. , FERRELL, BETTY ROLLING

Journal of Clinical Oncology | July 28, 2014 | Volume: 32 | Issue: 24 | Pages: 2587-2594

10.1200/jco.2013.55.0418 | PMID 25071116 Get It

A majority of cancer diagnoses and deaths occur in patients age ≥ 65 years. With the aging of the US population, the number of older adults with cancer will grow. Although the coming wave of older patients with cancer was anticipated in the early 1980s, when the need for more research on the cancer-aging interface was recognized, many knowledge gaps remain when it comes to treating older and/or frailer patients with cancer. Relatively little is known about the best way to balance the risks and benefits of existing cancer therapies in older patients; however, these patients continue to be underrepresented in clinical trials. Furthermore, the available clinical trials often do not include end points pertinent to the older adult population, such as preservation of function, cognition, and independence. As part of its ongoing effort to advance research in the field of geriatric oncology, the Cancer and Aging Research Group held a conference in November 2012 in collaboration with the National Cancer Institute, the National Institute on Aging, and the Alliance for Clinical Trials in Oncology. The goal was to develop recommendations and establish research guidelines for the design and implementation of therapeutic clinical trials for older and/or frail adults. The conference sought to identify knowledge gaps in cancer clinical trials for older adults and propose clinical trial designs to fill these gaps. The ultimate goal of this conference series is to develop research that will lead to evidence-based care for older and/or frail adults with cancer.
Response to Letter Regarding Article, “Flow-Gradient Patterns in Severe Aortic Stenosis With Preserved Ejection Fraction: Clinical Characteristics and Predictors of Survival”
Eleid, Mackram F. , Sorajja, Paul , Malouf, Joseph F., Scott, C.G., Pellikka, Patricia A. , Scott, Chrisopher G, Sorajja, Paul , Michelena, Héctor I. , Pellikka, Patricia A

Circulation | July 28, 2014 | Volume: 130 | Issue: 5 | Pages: No page available

10.1161/circulationaha.114.009358 | PMID 25070557 Get It